| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
GSK4112 is a novel and potent Rev-erbα agonist with EC50 of 0.4 μM in a biochemical assay measuring the interaction between Rev-erbα and a peptide from the nuclear receptor corepressor-1 (NCoR). The nuclear heme receptor Rev-erb is studied in detail using the small molecule chemical probe GSK4112. Studies of the orphan nuclear receptor Rev-erb'sfunctionas a heme sensor and regulator of metabolic and circadian signaling will be made possible by the discovery of nonporphyrin ligands for the receptor. GSK4112 and heme were rivals. 1 functioned as a Rev-erb agonist in cells to suppress the expression of the circadian target gene bmal1. Additionally, GSK4112 decreased glucose output in primary hepatocytes and suppressed the expression of gluconeogenic genes in liver cells. As a result, GSK4112 can be used as a chemical probe to examine how Rev-erb controls metabolic pathways, circadian biology, and transcriptional repression. A starting point for the design of Rev-erb chemical probes with in vivo pharmacological activity could be 1 as well.
| Targets |
Rev-erbα (EC50 = 0.4 μM)
|
|---|---|
| ln Vitro |
GSK4112 (0-100 μM; 1 h) interacts with Rev-erbα with an EC50 value of 0.4 μM[1].
GSK4112 (10 μM; 6 h) recruits HDAC3, modulates the impact of Rev-erbα on oscillation of hepatic gene expression, and represses the expression of bmal1 and the target genes linked to the pathway of gluconeogenesis[1]. GSK4112 (10 μM; 16 h) produce less glucose output in murine hepatocytes[1]. |
| ln Vivo |
GSK4112 (25 mg/kg; i.p. 0.5 h before Jo2 exposure) reduces the hepatic damage brought on by Fas[2].
|
| References |
| Molecular Formula |
C18H21CLN2O4S
|
|---|---|
| Molecular Weight |
396.888342618942
|
| Exact Mass |
396.0911
|
| Elemental Analysis |
C, 54.47; H, 5.33; Cl, 8.93; N, 7.06; O, 16.12; S, 8.08
|
| CAS # |
1216744-19-2
|
| Related CAS # |
1216744-19-2
|
| Appearance |
Solid powder
|
| SMILES |
CC(C)(C)OC(=O)CN(CC1=CC=C(C=C1)Cl)CC2=CC=C(S2)[N+](=O)[O-]
|
| InChi Key |
WYSLOKHVFKLWOU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H21ClN2O4S/c1-18(2,3)25-17(22)12-20(10-13-4-6-14(19)7-5-13)11-15-8-9-16(26-15)21(23)24/h4-9H,10-12H2,1-3H3
|
| Chemical Name |
tert-butyl 2-[(4-chlorophenyl)methyl-[(5-nitrothiophen-2-yl)methyl]amino]acetate
|
| Synonyms |
GSK4112; GSK 4112; GSK-4112
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 25~68 mg/mL (63.0~171.3 mM)
Ethanol: ~3 mg/mL (~7.6 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.30 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (6.30 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.30 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5196 mL | 12.5979 mL | 25.1959 mL | |
| 5 mM | 0.5039 mL | 2.5196 mL | 5.0392 mL | |
| 10 mM | 0.2520 mL | 1.2598 mL | 2.5196 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
